Navigation Links
Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF)

GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positive interim results from the ongoing Phase I study of its lead development programme, ALX-0081, an anti-thrombotic treatment. ALX-0081 is a novel ´first-in-class´ therapeutic Nanobody® targeting von Willebrand Factor (vWF), which can reduce the risk of thrombosis in patients with acute coronary syndrome.

The Phase I study in healthy volunteers is designed to assess safety, tolerability and pharmacokinetics of ALX-0081. It will also analyse pharmacodynamic effects of ALX-0081 to confirm its high potency. It is a double-blind, placebo-controlled trial in healthy male volunteers at a single center in Europe.

The study was initiated during the first quarter of 2007. The interim analysis indicates:

- the desired pharmacodynamic effect was observed as anticipated indicating the high potency of ALX-0081

- ALX-0081 was well tolerated and showed no serious adverse effects or dose limiting toxicity

The final results are anticipated to be available by the end of September 2007.

Dr Edwin Moses, CEO and Chairman said: "We are very encouraged by the positive results of our first Nanobody® in clinical development which is believed to be the first ever single domain antibody human trial. This is a significant milestone for Ablynx and demonstrates the success of Ablynx´s powerful discovery platform."

About ALX-0081
Through its novel, highly selective mode of action, ALX-0081 is intended to prevent arterial thrombosis, without interfering with the desired haemostatis (wound healing) in the patient which results in less bleeding complications. Pre-clinical in vivo studies confirmed Ablynx´s belief that ALX-0081 has unique potential to set a new standard in anti-thrombotic therapy based on its immediate onset of action, its high potency and significantly improved safety compared to the
'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/30/2014)... -- A study using a relatively new imaging tool, ... the composition of carotid artery disease and has the ... disease, a leading cause of stroke. ... 2010 and May 2012, was featured in the June ... College of Cardiology (JACC) Cardiovascular Interventions. Interventional cardiologist ...
(Date:9/30/2014)... Sept. 30, 2014 BioStructures, LLC has ... Association of Tissue Banks (AATB), it was announced ... Officer. Accreditation follows an intensive nine-month ... trained AATB inspector.  It establishes that the level ... facility meets or exceeds the standards set by ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Pharma,s eFlow,electronic nebulizer was included in Gilead,s (Nasdaq: ... to the U.S. Food and Drug Administration,(FDA) for ... mg,three times daily). Aztreonam lysine for inhalation, delivered ... people with cystic fibrosis,(CF) who have pulmonary Pseudomonas ...
... large, randomized Phase III trials of VELCADE in front-line, ... ... Mass., Nov. 26 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) today ... studies are scheduled to be,featured at the 49th ASH Annual Meeting ...
Cached Medicine Technology:PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 2PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 2New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 4New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 6
(Date:9/30/2014)... no stranger to the children of Tanzania. What is ... clinical services, including reliable diagnosis and evidence-based treatments. There ... use in Swahili, a major language of the region. ... University and the University of Georgia (UGA) describe a ... sites in the country and found to be effective ...
(Date:9/30/2014)... 2014 Integrated Medicine Alliance , ... another new medical specialty practice through a unique partnership ... will be located within the company’s Shrewsbury location and ... Isaac Tawfik of American Heart Center, P.C., a highly ... will offer Integrated Medicine Alliance patients top notch cardiovascular ...
(Date:9/30/2014)... September 30, 2014 Glycodrive , ... Nutraceuticals designed to help maximize lean, strong muscle growth ... body’s absorption of glucose has caught the attention of ... main purpose behind Glycodrive is to help the body ... reports Michaels. “Carbs are essential in the muscle-building process, ...
(Date:9/30/2014)... 2014 VisitandCare.com reports that ... gone up more than 79 percent in 2014, marking ... also reported total revenue tripled for its entirety of ... professional strategy has allowed them to partner with ... patient comfort and privacy — with state-of-the-art surgical atmospheres ...
(Date:9/30/2014)... 2014 A group of Americans is headed ... epidemic that, left unchecked, could create a catastrophic, global pandemic. ... to Africa. John Rogers, the Executive Director the Eugene Bell ... fight a disease most think mankind conquered long ago: tuberculosis. ... ago is on the comeback in several countries - what’s ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... program delivered by over 500 peer volunteers significantly reduces ... researcher Dr. Janusz Kaczorowski told the Canadian Stroke Congress ... Program (CHAP), family physicians in 20 mid-sized Ontario communities ... assessment sessions held at local pharmacies over a 10 ...
... British Columbia (June 7, 2010) Researchers from the ... University of British Columbia today released a comprehensive study ... HIV treatment would create significant benefits for individuals infected ... peer-reviewed mathematical modeling study, published in the research journal ...
... Susan G. Komen for the Cure has appointed V. ... Council. Jordan, a member of the National Academy of ... department of oncology at the Lombardi Comprehensive Cancer Center at ... appointment to the Komen Scientific Advisory Council is reserved for ...
... WASHINGTON, June 7, 2010 Those social drinkers who order ... default "well" liquor. Are they just vodka snobs, who pay ... possibly taste much different than its $6 counterpart? Or is ... claim to taste in America,s favorite hard liquor? ...
... survivors diagnosed later with non-melanoma skin cancer may be ... 15 years, according to research led by St. Jude ... survivors in this Childhood Cancer Survivor Study (CCSS) who ... developed another more aggressive cancer within 15 years, said ...
... in German . Early detection is the ... lump turns out to be a malignant tumor. To find ... biopsy and examine the removed tissue under the microscope. This ... also highly time consuming. Research scientists at the Fraunhofer Institute ...
Cached Medicine News:Health News:A good CHAP reduces rates of heart disease and stroke in communities. 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 3Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 2Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 3Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 4Health News:Brand preference may be in the drink, not in the head 2Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:Detecting tumors faster 2
Anatomically designed 3 cervical foam collar...
One-piece rigid cervical collar is designed to fit securely around the neck and mandible to provide immobilization and support of the cervical region...
This model utilizes the Malibu Soft Cervical Collar with a Thoracic Extension....
Model C-10 is a four post cervical orthosis which controls flexion, extension, lateral flexion, rotation, and axial motion. Each post may be individually adjusted in height....
Medicine Products: